On February 12th, Gilead Science reported a fourth quarter revenue of $7.57 billion, with analysts expecting $7.13 billion; Q4 revenue of $7.57 billion, analysts expect $7.13 billion; Veklury’s revenue for the fourth quarter was $337 million, with analysts expecting $380.1 million; Trodelvy’s revenue for the fourth quarter was $355 million, with analysts expecting $321.5 million. The company expects an adjusted EPS of $7.7-8.1 for 2025, while analysts expect $7.54; The company expects product sales to reach 28.2-28.6 billion US dollars in 2025, with analysts expecting 28.07 billion US dollars; The company expects Veklury’s revenue to be $1.4 billion by 2025.
Scan code to share